Subcategories:

Sort by:

select Language:



2015 Pipeline Report HIV, Hepatitis C virus (HCV), and Tuberculosis (TB)

Polly Clayden, Simon Collins, Mike Frick, et al., Eds.: A. Benzacar; HIV i-BASE/TREATMENT ACTION GROUP, (2015)


Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development
http://www.pipelinereport.org/sites/g/files/g57552...


Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

World Health Organization, (2015)


The recommendations in these guidelines promote the use of simple, non-invasive diagnostic tests to assess the stage of liver disease and eligibility for treatment; prioritize treatment for those with most advanced liver disease and at greatest risk of mortality; and recommend the preferred use of nucleos(t)ide analogues with a high barrier to drug resistance (tenofovir and entecavir, and entecavir in children aged 2–11 years) for first- and second-line treatment. Recommendations for the treatment of HBV/HIV-coinfected persons are based on the WHO 2013 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, which will be updated in 2015.
http://apps.who.int/iris/bitstream/10665/154590/1/...


Hepatitis B (chronic): Diagnosis and management of chronic hepatitis B in children, young people and adults

Aftab Ala, Elizabeth Boxall, Steven Bradley et al., Eds.: National Clinical Guideline Centre, (2013)


Clinical guideline, Methods, Evidence and Recommendations In this guideline the following is covered: information needs of people with chronic hep titis B and their carers; where children, young people and adults with chronic hepatitis B a- should be assessed; assessment of liver disease, including the use of non-invasive tests and genotype testing; criteria for offering antiviral treatment; the efficacy, safety and cost effectiveness of currently available treatments; selection of first-line therapy; management of treatment failure or drug resistance; prophylactic treatment during im- munosuppressive therapy; and monitoring for treatment response
http://www.ncbi.nlm.nih.gov/books/NBK254250/pdf/TO...


5 hits